Brivaracetam Patent Expiration
Brivaracetam is used for managing partial-onset seizures in patients with epilepsy aged 4 years and older. It was first introduced by Ucb Inc
Brivaracetam Patents
Given below is the list of patents protecting Brivaracetam, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Briviact | US10729653 | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives | Apr 09, 2030 | Ucb Inc |
| Briviact | US6911461 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
Feb 21, 2026
(Expired) | Ucb Inc |
| Briviact | US6784197 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
Feb 21, 2021
(Expired) | Ucb Inc |
| Briviact | US8492416 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
Feb 21, 2021
(Expired) | Ucb Inc |
Brivaracetam's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Brivaracetam:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy | UCB Biopharma SRL | NA |
COMPLETED
(Aug 1, 2026)
| PHASE3 |
| A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy | UCB Biopharma SRL | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE3 |
| Brivaracetam Bioequivalence Assessment | Zodiac Produtos Farmaceuticos S.A. | NA |
COMPLETED
(Aug 1, 2026)
| PHASE1 |
| A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures | UCB Biopharma SRL | NA |
RECRUITING
(Jul 1, 2026)
| PHASE3 |
| Long-term Safety and Efficacy of Adjunctive Brivaracetam in Chinese Patients With Uncontrolled Focal Epilepsy | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | NA |
COMPLETED
(Apr 1, 2026)
| PHASE3 |